MXPA05012101A - Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. - Google Patents

Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.

Info

Publication number
MXPA05012101A
MXPA05012101A MXPA05012101A MXPA05012101A MXPA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A MX PA05012101 A MXPA05012101 A MX PA05012101A
Authority
MX
Mexico
Prior art keywords
binding pocket
hepatitis
ns5b polymerase
polymerase inhibitor
hcv ns5b
Prior art date
Application number
MXPA05012101A
Other languages
English (en)
Inventor
Steven Laplante
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MXPA05012101A publication Critical patent/MXPA05012101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

La polimerasa NS5B del HCV, cuando se compleja con ciertos inhibidores, adopta una conformacion en la que la region del bucle de dedo definida por los residuos aminoacidos 18 a 35 esta desplazada para exponer un bolsillo de union generalmente definido por los residuos de aminoacidos 392, 393, 395, 396, 399, 424, 425, 428, 429, 492, 493, 494, 495, 496, 500 y 503. Este bolsillo de union recientemente expuesto define una nueva diana en la busqueda de entidades quimicas adicionales que son capaces de unirse a NS5B del HCV y de modular, o preferiblemente inhibir, la actividad de polimerasa NS5B del HCV.
MXPA05012101A 2003-05-09 2004-05-05 Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c. MXPA05012101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46960403P 2003-05-09 2003-05-09
PCT/CA2004/000676 WO2004099241A1 (en) 2003-05-09 2004-05-05 Hepatitis c virus ns5b polymerase inhibitor binding pocket

Publications (1)

Publication Number Publication Date
MXPA05012101A true MXPA05012101A (es) 2006-02-08

Family

ID=33435247

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012101A MXPA05012101A (es) 2003-05-09 2004-05-05 Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.

Country Status (12)

Country Link
US (1) US7386398B2 (es)
EP (1) EP1625154B1 (es)
JP (1) JP4584909B2 (es)
KR (1) KR101164070B1 (es)
CN (1) CN100457776C (es)
AU (1) AU2004235848B2 (es)
CA (1) CA2522574C (es)
DK (1) DK1625154T3 (es)
ES (1) ES2456702T3 (es)
IL (1) IL171800A (es)
MX (1) MXPA05012101A (es)
WO (1) WO2004099241A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8535334B2 (en) * 2007-04-17 2013-09-17 Lazarus Effect, Inc. Complex wire formed devices
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2010535155A (ja) * 2007-08-03 2010-11-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼ阻害剤
WO2009033183A2 (en) * 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
BRPI0703586B1 (pt) * 2007-10-19 2018-02-06 Braskem S.A Catalisador metaloceno suportado, e, copolímeros de etileno com alfa-olefinas de alto e ultra alto peso molecular
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
NZ593806A (en) * 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
TW201039826A (en) * 2009-01-12 2010-11-16 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
CA2753313A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
AU2010266570A1 (en) * 2009-06-30 2012-01-19 Siga Technologies, Inc. Treatment and prevention of Dengue virus infections
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
WO2011026024A2 (en) * 2009-08-31 2011-03-03 Glaxosmithkline Llc Imidazo [4,5-d] pyridazine compounds for treating viral infections
US20110065782A1 (en) * 2009-09-15 2011-03-17 Malliavin Therese Methods of identifying compounds that inhibit the activation of a biomolecule and methods of treatment using the compounds
WO2011103063A1 (en) * 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
US20130296311A1 (en) * 2010-05-28 2013-11-07 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
AU2011320696B2 (en) 2010-10-26 2016-07-21 Presidio Pharmaceuticals, Inc. Inhibitors of Hepatitis C Virus
US8741614B2 (en) * 2010-11-02 2014-06-03 Probiodrug Ag Crystal structure of isoglutaminyl cyclase
KR101835474B1 (ko) 2010-11-17 2018-03-08 길리애드 파마셋 엘엘씨 항바이러스 화합물
US20150232455A1 (en) * 2010-12-15 2015-08-20 Allan C. Krueger Anti-viral compounds
JP6041877B2 (ja) * 2011-08-12 2016-12-14 サザン リサーチ インスティテュート キナゾリノン類似体及び特定のウイルス感染症の治療又は予防へのキナゾリノン類似体の使用
PE20171444A1 (es) 2011-11-16 2017-09-29 Gilead Pharmasset Llc Compuestos antivirales
DK2794628T3 (en) 2011-12-20 2017-07-10 Riboscience Llc 4'-AZIDO-3'-FLUORO-SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION
US20150087045A1 (en) * 2012-01-13 2015-03-26 Gilead Pharmassset Llc Crystal structure of hcv polymerase complexes and methods of use
US20130309196A1 (en) * 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9167288B2 (en) 2013-03-15 2015-10-20 Universal Electronics Inc. System and method for optimizing memory usage in a universal controlling device
MY186547A (en) 2013-05-16 2021-07-26 Riboscience Llc 4?-fluoro-2?-methyl substituted nucleoside derivatives
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
MA38678A1 (fr) 2013-05-16 2017-07-31 Riboscience Llc Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
KR20160045136A (ko) 2013-08-26 2016-04-26 이난타 파마슈티칼스, 인코포레이티드 C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
US9718851B2 (en) 2014-11-06 2017-08-01 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104530189B (zh) * 2014-12-16 2017-11-14 郑州大学第一附属医院 丙型肝炎病毒ns5b rna聚合酶抑制多肽序列及其用途
TW201919649A (zh) 2017-09-21 2019-06-01 美商里伯賽恩斯有限責任公司 作為ｈｃｖ ｒｎａ複製抑制劑之經４′－氟－２′－甲基取代之核苷衍生物
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5528559A (en) * 1995-06-23 1996-06-18 Motorola, Inc. Multiple display timepiece
EP1076692A2 (en) * 1998-05-04 2001-02-21 Vertex Pharmaceuticals Incorporated Crystallizable jnk complexes
US6434489B1 (en) * 2000-04-03 2002-08-13 Schering Corporation Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1256628A3 (en) * 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
AU2002339901A2 (en) * 2001-09-06 2003-03-24 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors

Also Published As

Publication number Publication date
CN100457776C (zh) 2009-02-04
JP4584909B2 (ja) 2010-11-24
EP1625154B1 (en) 2014-01-08
KR20060011861A (ko) 2006-02-03
ES2456702T3 (es) 2014-04-23
CA2522574C (en) 2015-07-07
JP2007534292A (ja) 2007-11-29
AU2004235848B2 (en) 2011-08-04
EP1625154A1 (en) 2006-02-15
CN1820022A (zh) 2006-08-16
DK1625154T3 (da) 2014-02-24
WO2004099241A1 (en) 2004-11-18
CA2522574A1 (en) 2004-11-18
AU2004235848A1 (en) 2004-11-18
KR101164070B1 (ko) 2012-07-12
IL171800A (en) 2013-06-27
US20050003348A1 (en) 2005-01-06
US7386398B2 (en) 2008-06-10

Similar Documents

Publication Publication Date Title
MXPA05012101A (es) Bolsillo de union al inhibidor de polimerasa ns5b del virus de la hepatitis c.
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
UA86962C2 (en) Viral polymerase inhibitors
WO2001074768A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
ATE474827T1 (de) Hcv-replikationshemmer
WO2006086381A3 (en) Hepatitis c virus inhibitors
RS51294B (sr) Inhibitorna jedinjenja za hepatitis c
DE60319820D1 (de) Pyrazoloä1,5-aüpyrimidin-verbindungen als antivirale agentien
ATE542826T1 (de) Inhibitoren des hepatitis-c-virus
TW200728317A (en) Macrocylic inhibitors of hepatitis C virus
BRPI0414571A (pt) peptìdeos macrocìclicos ativos contra o vìrus da hepatite c
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
SG159385A1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
DE60336550D1 (de) Inhibitoren des hepatitis-c-virus
RS67004A (en) Macrocyclic peptides active against the hepatitis c virus
MX2007000007A (es) Inhibidores de polimerasa viral.
MXPA05008106A (es) Inhibidores del virus de la hepatitis c, composiciones y tratamientos que los emplean.
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
EA200900676A1 (ru) Ингибиторы вируса гепатита с
WO2005000308A3 (en) Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
TW200610766A (en) A liver-specific chimeric regulatory sequence and use thereof
WO2003051910A3 (en) Inhibitors of hepatitis c virus protease

Legal Events

Date Code Title Description
FG Grant or registration